Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is trading at $111.56, about ₹10,716 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, down 1.18% today. Indian residents can buy Halozyme Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$111.03
Today's high
$114.52
52 week low
$61.23
52 week high
$116.85
HALO opened at $112.89, closed previously at $112.89, and has traded between $61.23 and $116.85 over the past 52 weeks.
About
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Key statistics
Avg. volume
2.04M
Market cap
$13.23B
P/E Ratio
31.69
Price-to-sales ratio
7.95
Enterprise value
$10.07B
Free cash flow yield
7.99%
Debt-to-equity ratio
14.95
Return on equity
649.18%
ROIC
23.59%
Beta
0.88
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$1.40B
Earnings per share
$2.64
Free cash flow
$644.59M
Net profit margin
24.86%
Gross margin
78.18%
EBITDA
$573.05M
Revenue growth
37.55%
Similar securities
This is not an investment recommendation
How to buy Halozyme Therapeutics from India
Indian residents can buy Halozyme Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Halozyme Therapeutics and place an order
Find Halozyme Therapeutics by name or by its ticker, HALO, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Halozyme Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Halozyme Therapeutics position in USD and INR. Halozyme Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Halozyme Therapeutics from India
Trading and taxes when buying Halozyme Therapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneHalozyme Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Halozyme Therapeutics stock?
Yes. Halozyme Therapeutics (HALO) has been listed on NASDAQ since 2004, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Halozyme Therapeutics share cost in rupees?
One Halozyme Therapeutics share is $111.56 — about ₹10,716 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the Halozyme Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Halozyme Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy Halozyme Therapeutics with less than the price of one share?
Yes. A whole Halozyme Therapeutics share is $111.56, but there is no minimum trade size: you enter a rupee or dollar amount and receive the matching fraction.
How are gains on Halozyme Therapeutics shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Halozyme Therapeutics price. Paasa issues a capital-gains statement for your return.
Does Halozyme Therapeutics pay a dividend?
No. Halozyme Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Halozyme Therapeutics from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Halozyme Therapeutics shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Halozyme Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Halozyme Therapeutics holding, its cost and its closing value.
How do I sell Halozyme Therapeutics and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.